Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
) missed Wall Street consensus estimates on Mounjaro sales for the first quarter of the year, but its GLP-1 products, including Zepbound , still contributed to 26% sales growth year over year in the quarter.
"I'm really encouraged by the earnings beat as well, suggesting that the profitability of these products is very high and likely to increase profits going forward," Seigerman said. Lilly reported total revenues of $8.8 billion in the quarter, up roughly $2 billion from revenues of nearly $7 billion in the same quarter in 2023.is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics.
Shopify stock was climbing Monday after an analyst upgraded shares of the e-commerce platform on confidence in growth. Citi analyst Tyler Radke upgraded shares of Shopify to Buy from Neutral, and increased his target price to $105 from $93, which implies a 47% increase in the stock price as of Friday’s close. “Our Deep-Dive analysis into SHOP’s Merchant Solutions business gives us confidence in SHOP’s long-term growth,” Radke wrote in a research note.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Weight-loss drug shortage result of 'unprecedented demand'Certain doses of Eli Lilly's (LLY) GLP-1 weight loss drugs Zepbound and Mounjaro are facing a supply shortage, much like competitor Novo Nordisk's (NVO) own ...
Read more »
Lilly Raises 2024 Guidance as Zepbound Keeps Flying Off ShelvesEli Lilly & Co. raised its annual outlook for sales and profit as the company labored to satisfy soaring demand for its blockbuster weight-loss and diabetes drugs.
Read more »
Almost Every Dose of Lilly’s Zepbound Is in Shortage, FDA SaysNearly all doses of Eli Lilly & Co.’s weight-loss drug Zepbound will now be in shortage through at least the middle of the year as demand for the blockbuster injections continues to surge.
Read more »
Eli Lilly stock jumps on weight-loss drug sales forecastShares of Eli Lilly (LLY) are moving higher on Tuesday morning as the company reported its first-quarter earnings results, revealing a 26% year-over-year...
Read more »
Eli Lilly's GLP-1 demand drives up stock price post-Q1 resultsShares of Eli Lilly (LLY) are soaring in Tuesday's trading session after the company raised its full-year guidance, driven by the surging demand for its...
Read more »
Eli Lilly's weight loss drug could help sleep apnea patientsShares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial...
Read more »